சோதனை கண் மருத்துவம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சோதனை கண் மருத்துவம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சோதனை கண் மருத்துவம் Today - Breaking & Trending Today

How a tube the width of a hair saved Michael Rosen's eyesight


Former Children’s Laureate Michael Rosen spent 40 days in an induced coma last year after developing Covid and when he finally woke up last May, he was a much-changed man.
He discovered that he’d almost died or, as he puts it, ‘disappeared’ several times. When he came to, his muscles had weakened through lack of use, his breathing was laboured and he had to relearn basic skills, such as how to walk.
But what really hit Michael, 75, was how much his eyesight had changed. Whereas before he’d only needed weak glasses for reading, now he was struggling to see. ....

City Of , United Kingdom , Comunidad Autonoma De Cataluna , Dan Nguyen , Vik Sharma , Michael Rosen , University Of Barcelona , London Ophthalmology Centre , Former Children , Laureate Michael Rosen , North London , Royal Free Hospital , Graham Norton Show , Experimental Ophthalmology , Mid Cheshire Hospitals , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , காமுனிடட தன்னாட்சி டி கடலுள் , டான் ஂக்யந் , விக் ஷர்மா , மைக்கேல் ரோஸன் , பல்கலைக்கழகம் ஆஃப் பார்சிலோனா , லண்டன் கண் மருத்துவம் மையம் , முன்னாள் குழந்தைகள் , பரிசு பெற்றவர் மைக்கேல் ரோஸன் , வடக்கு லண்டன் ,

Investegate |Oxurion NV Announcements | Oxurion NV: Oxurion NV Business and Financial Update – FY 2020


 
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
 
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
 
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
 
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021.  The Company is in advanced discussions with potential investors in order to increase its cash position. ....

United States , Bruxelles Capitale , New York , France General , Region Flamande , Tom Graney , City Of , United Kingdom , Jean Feyen , Ramin Tadayoni , Grace Chang , Dominique Vanfleteren , Arshad Khanani , Sylvie Berrebi Frazer Hall , Los Angeles , Wouter Piepers , Jo Van Ginderachter , Claude Sander , Kathleen Paisley , Citigate Dewe Rogerson , Christopher Brinzey , Yale Law School , Ironwood Pharmaceuticals , Bascom Palmer Eye Institute Angiogenesis , Queen Mary University Of London , University Of Nevada ,